Guideline for pharmacological treatment of schizophrenia 2022.
出版信息
Neuropsychopharmacol Rep. 2025 Mar;45(1):e12497. doi: 10.1002/npr2.12497. Epub 2024 Nov 25.
Abstract
摘要
相似文献
1
Guideline for pharmacological treatment of schizophrenia 2022.《2022年精神分裂症药物治疗指南》
Neuropsychopharmacol Rep. 2025 Mar;45(1):e12497. doi: 10.1002/npr2.12497. Epub 2024 Nov 25.
2
Relationships Between Adherence to Guideline Recommendations for Pharmacological Therapy Among Clinicians and Psychotic Symptoms in Patients With Schizophrenia.临床医生对精神分裂症患者药物治疗指南建议的遵从度与患者精神病症状之间的关系。
Int J Neuropsychopharmacol. 2023 Aug 29;26(8):557-565. doi: 10.1093/ijnp/pyad037.
3
Effectiveness of a treatment guideline for schizophrenia in adolescents: Lessons from a middle-income country.青少年精神分裂症治疗指南的效果：来自中等收入国家的经验教训。
Aust N Z J Psychiatry. 2018 Feb;52(2):192-199. doi: 10.1177/0004867417726581. Epub 2017 Aug 23.
4
Developing the EPA guidance of pharmacological treatment of schizophrenia - results of a Delphi process.制定美国环境保护局精神分裂症药物治疗指南——德尔菲法的结果
Eur Psychiatry. 2025 Jan 30;68(1):e26. doi: 10.1192/j.eurpsy.2024.1794.
5
Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode.精神分裂症的药理学指南：首次发作建议的系统评价与比较
BMJ Open. 2017 Jan 6;7(1):e013881. doi: 10.1136/bmjopen-2016-013881.
6
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology.循证指南：英国精神药理学协会更新的精神分裂症药物治疗推荐。
J Psychopharmacol. 2020 Jan;34(1):3-78. doi: 10.1177/0269881119889296. Epub 2019 Dec 12.
7
[Clinical guidelines for the management of schizophrenia: Pharmacological and psychological interventions (III)].[精神分裂症管理临床指南：药物和心理干预（III）]
Psychiatriki. 2018 Oct-Dec;29(4):303-315. doi: 10.22365/jpsych.2018.294.303.
8
Treating schizophrenia: the quality of evidence behind treatment recommendations and how it can improve.治疗精神分裂症：治疗建议背后的证据质量以及如何改善。
BMJ Evid Based Med. 2020 Aug;25(4):138-142. doi: 10.1136/bmjebm-2019-111233. Epub 2019 Oct 31.
9
One-Year Outcome and Adherence to Pharmacological Guidelines in First-Episode Schizophrenia: Results From a Consecutive Cohort Study.首发精神分裂症患者的一年结局和药物治疗指南依从性：一项连续队列研究的结果。
J Clin Psychopharmacol. 2020 Nov/Dec;40(6):534-540. doi: 10.1097/JCP.0000000000001303.
10
Relationships between clinician adherence to guideline-recommended treatment and memory function in patients with schizophrenia.精神分裂症患者中临床医生对指南推荐治疗的依从性与记忆功能之间的关系。
J Psychiatr Res. 2025 May;185:169-176. doi: 10.1016/j.jpsychires.2025.03.054. Epub 2025 Mar 27.
引用本文的文献
1
Awareness and management of cognitive impairment associated with schizophrenia in psychiatrists and patients: Results from a cross-sectional survey.精神科医生和患者对精神分裂症相关认知障碍的认识与管理：一项横断面调查结果
Schizophr Res Cogn. 2025 Jun 27;42:100375. doi: 10.1016/j.scog.2025.100375. eCollection 2025 Dec.
本文引用的文献
1
Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".日本神经精神药理学学会：《精神分裂症药物治疗指南》
Neuropsychopharmacol Rep. 2021 Sep;41(3):266-324. doi: 10.1002/npr2.12193. Epub 2021 Aug 12.
2
Psychosocial interventions in schizophrenia: Focus on guidelines.精神分裂症的心理社会干预：聚焦指南。
Int J Soc Psychiatry. 2020 Dec;66(8):735-747. doi: 10.1177/0020764020934827. Epub 2020 Jun 27.
3
Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment.精神分裂症的阴性症状：识别、评估及治疗的综述与临床指南
Neuropsychiatr Dis Treat. 2020 Feb 21;16:519-534. doi: 10.2147/NDT.S225643. eCollection 2020.
4
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.18种抗精神病药物对精神分裂症患者代谢功能的比较效应、代谢失调的预测因素及其与精神病理学的关联：一项系统评价和网状Meta分析
Lancet Psychiatry. 2020 Jan;7(1):64-77. doi: 10.1016/S2215-0366(19)30416-X. Epub 2019 Dec 17.
5
Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.与精神分裂症中成功减少抗精神病药物剂量相关的因素：前瞻性临床试验的系统评价和随机对照试验的荟萃分析。
Neuropsychopharmacology. 2020 Apr;45(5):887-901. doi: 10.1038/s41386-019-0573-7. Epub 2019 Nov 26.
6
Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists.治疗抵抗性精神分裂症患者的特征、负担和药物治疗：来自对 204 名美国精神科医生的调查结果。
BMC Psychiatry. 2019 Nov 14;19(1):362. doi: 10.1186/s12888-019-2318-x.
7
Determinants of clinical, functional and personal recovery for people with schizophrenia and other severe mental illnesses: A cross-sectional analysis.精神分裂症和其他严重精神疾病患者的临床、功能和个人康复的决定因素：一项横断面分析。
PLoS One. 2019 Sep 18;14(9):e0222378. doi: 10.1371/journal.pone.0222378. eCollection 2019.
8
Relationship between polydipsia and antipsychotics: A systematic review of clinical studies and case reports.多饮与抗精神病药物的关系：临床研究和病例报告的系统评价。
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jan 10;96:109756. doi: 10.1016/j.pnpbp.2019.109756. Epub 2019 Aug 28.
9
British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication.英国心脏节律学会关于抗精神病药物治疗中出现QT间期延长患者管理的临床实践指南。
Arrhythm Electrophysiol Rev. 2019 Jul;8(3):161-165. doi: 10.15420/aer.2019.8.3.G1.
10
Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review.氯氮平使用者发热的临床决定因素及其对治疗管理的意义：叙述性综述。
Schizophr Res. 2019 Sep;211:1-9. doi: 10.1016/j.schres.2019.07.040. Epub 2019 Aug 1.
Zotero 插件